Volume: 12 Issue: 2
Year: 2024, Page: 61-69, Doi: https://doi.org/10.47799/pimr.1202.12
Received: July 13, 2024 Accepted: July 26, 2024 Published: Aug. 22, 2024
Background: Obstructed total anomalous pulmonary venous connection (OTAPVC) typically presents with severe cardiovascular decompensation and requires urgent surgical management. Pulmonary arterial hypertension (PAH) is a major risk factor affecting mortality. Perioperative management focuses on providing inotropic support and managing potential pulmonary hypertensive episodes. The aim of this study was to determine the outcome of patients with high pulmonary arterial pressure (PAP) with milrinone alone and a combination of milrinone and inhaled nitric oxide (INO). Material and Methods: After the approval of the ethical committee, this single-centre prospective randomised and observational study was conducted over a period of two years among eighty-six patients with obstructed TAPVC repair with severe PAH. Group-I patients received milrinone, and Group-II patients received both milrinone (after aortic cross clamp removal) and INO during the post-operative period at the cardiac care unit (CCU). Clinical outcomes such as ventilation time, length of stay (LOS) in the CCU, LOS in the hospital, complications, and hospital mortality were compared between the two groups. Result: The average ventilation time, LOS in CCU, and LOS in hospital for group I were 96.82 ± 19.46 hours, 10.91 ± 7.53 days, and 14.46 ± 7.58 days, respectively, and for group II, it was 85.14 ± 15.79 hours, 7.28 ± 3.68 days, and 10.21 ± 3.14 days, respectively, which was statistically significantly lower for group II. Reintubation, RV dysfunction, and hospital mortality were 16.3%, 37.2%, and 6.9% in group I, and 4.8%, 14.6%, and 2.4% in group II, respectively. The P value for each variable was significant < 0.05 (except mortality). Conclusion: Preoperative obstruction is a risk factor for postoperative obstruction, as 235 patients with obstructed TAPVC had severe PAH (39.98%) in this study. Management of severe PAH with a combination of milrinone and INO had a better outcome than milrinone alone.
Keywords: Cyanotic congenital heart disease, TAPVC, Milrinone, Inhaled Nitric Oxide
Mounir, R, Nya, F, Mohammed, B, Ayad, A & Bamous, M . 2020. Adults forms of scimitar syndrome. J Card Surg 35(7):1697–1699.
Tailor, K B, Dharmani, K H, Kadam, S V, Kattana, H B & Rao, S G . 2021. A single center, retrospective analysis of total anomalous pulmonary venous connection repair early outcome at a tertiary care center in India. Ann Card Anaesth 24(3):333–338.
Seale, A N, Uemura, H, Webber, S A, Partridge, J, Roughton, M & Ho, S Y . 2010. Total anomalous pulmonary venous connection: morphology and outcome from an international population-based study. Circulation 122:2718–2744.
Craig, J M, Darling, R C & Rothney, W B . 1957. Total pulmonary venous drainage into the right side of the heart; report of 17 autopsied cases not associated with other major cardiovascular anomalies. Lab Invest 6(1):44–64.
Seale, A N, Uemura, H, Webber, S A, Partridge, J, Roughton, M, Ho, S Y, Mccarthy, K P, Jones, S, Shaughnessy, L, Sunnegardh, J, Hanseus, K, Berggren, H, Johansson, S, Rigby, M L, Keeton, B R & Daubeney, P E . 2010. British Congenital Cardiac Association. Total anomalous pulmonary venous connection: morphology and outcome from an international population-based study. Circulation 21(25):2718–2744.
White, B R, Ho, Y D, Faerber, J A, Katcoff, H, Glatz, A C, Mascio, C E, Stephens, P & Cohen, M S . 2019. Repair of total anomalous pulmonary venous connection: risk factors for postoperative obstruction. Ann Thorac Surg 108(1):122–129.
Singh, S, Okyere, I, Annamalai, A & Singh, A . 2022. A Study of the effectiveness of lidocaine to treat severe pulmonary vascular constriction induced by protamine. Perspectivesin Medical Research 10(01):11–19.
Hancock Friesen, C L, Zurakowski, D, Thiagarajan, R R, Forbess, J M, Del Nido, P J & Mayer, J E . 2005. Total anomalous pulmonary venous connection: An analysis of current management strategies in a single institution. Ann Thorac Surg 79:595–606.
Kanazawa, T, Shimizu, K & Iwasaki, T . 2021. Perioperative milrinone infusion improves one-year survival after Norwood-Sano procedure. J Cardiothorac Vasc Anesth 35:2073–2081.
Nicholls, M . 2019. Nitric oxide discovery Nobel Prize winners: Robert F. Furchgott, Louis J. Ignarro, and Ferid Murad shared the Noble Prize in 1998 for their discoveries concerning nitric oxide as a signalling molecule in the cardiovascular system. Eur. Heart J 40:1747–1749.
Yu, B, Ichinose, F, Bloch, D B & Zapol, W M . 2019. Inhaled nitric oxide. Br. J. Pharmacol 176:246–255.
Sulaiman, Al, Korayem, K, Altebainawi, G B, A F, Harbi, Al, S, Alharthi, Alissa A, Kensara, A, Alfahed, R, Vishwakarma, A, R, Haji, Al & H . 2022. Evaluation of inhaled nitric oxide (iNO) treatment for moderate-to-severe ARDS in critically ill patients with COVID-19: A multicenter cohort study. Crit. Care 26:304.
Maruyama, K, Maruyama, J & Sawada, H . Endogenous and Inhaled Nitric Oxide for the Treatment of Pulmonary Hypertension. http://dx.doi.org/10.5772/intechopen.89381
Mcmullan, D M, Bekker, J M, Johengen, M J, Hendricks-Munoz, K, Gerrets, R, Black, S M & Fineman, J R . 2001. Inhaled nitric oxide-induced rebound pulmonary hypertension: role for endothelin-1. Am J Physiol Heart Circ Physiol 280(2):777–85.
Singh, Sanjeev . 2014. Does Inhalational Nitrous Oxide Affect Induction Dose of Propofol and Haemodynamic. International Journal of Anesthesia and Clinical Medicine 2(5):32–39.
Kamenshchikov, N O, Berra, L & Carroll, R W . 2022. Therapeutic effects of inhaled nitric oxide therapy in COVID-19 patients. Biomedicines 10:369.
Singh, S, Singh, A, Rahman, M M, Mahrous, D E & Singh, L C . 2024. Is the combination of conventional ultrafiltration and modified ultrafiltration superior to modified ultrafiltration in pediatric open-heart surgery. J Med Soc 38:45–53.
Cai, J, Su, Z, Shi, Z, Zhou, Y, Xu, Z & Xu, Z . 2008. Nitric oxide and milrinone: Combined effect on pulmonary circulation after Fontan-type procedure: A prospective, randomized study. Ann Thorac Surg 86:882–890.
Olson, J S, Foley, E W, Rogge, C, Tsai, A L, Doyle, M P & Lemon, D D . 2004. No scavenging and the hypertensive effect of hemoglobin-based blood substitutes. Free. Radic. Biol. Med 36:685–697.
Signori, D, Magliocca, A, Hayashida, K, Graw, J A, Malhotra, R, Bellani, G, Berra, L & Rezoagli, E . 2022. Inhaled nitric oxide: Role in the pathophysiology of cardio-cerebrovascular and respiratory diseases. Intensive Care Med 10:28.
Stamler, J S . 1995. Inhaled nitric oxide as a therapeutic modality: Is it good or bad? New Horiz 3:9–11.
Morales, D L, Braud, B E, Booth, J H, Graves, D E, Heinle, J S & Mckenzie, E D . 2006. Heterotaxy patients with total anomalous pulmonary venous return: Improving surgical results. Ann Thorac Surg 82:1621–1629.
Singh, S, Okyere, I & Singh, A . 2022. Paediatric Cardiac Anaesthesia Perspective in Komfo Anokye Teaching Hospital Kumasi: A 10-year review. Niger J Med 31:202–209.
Kamenshchikov, N O, Duong, N & Berra, L . 2023. Nitric oxide in cardiac surgery: A review article. Biomedicines 11(4):1085.
Karamlou, T, Gurofsky, R, Sukhni, Al, Coles, E, Williams, J G, Caldarone, W G & C A . 2007. Factors associated with mortality and reoperation in 377 children with total anomalous pulmonary venous connection. Circulation 115:1591–1599.
©2024 (Sanjeev Singh) et al. This is an open-access journal, and arƟcles are distributed under the terms of the Creative Commons Attribution License CC-BY 4.0. (https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are credited.
Singh S, Mahrous DE, Singh B, Mohammad Ateequr Rahman M, Bandoh I, Singh A. A ProspecƟve Randomised Observational Study of Obstructed Total Anamalous Pulmonary Venous Connection (TAPVC) Repair Patients with Milrinone Versus Milrinone and Inhaled Nitric Oxide . Perspectives in Medical Research. 2024;12(2):61-69 DOI: 10.47799/pimr.1202.12